Shenxian Shengmai Oral Liquid for Treatment of Bradycardia:A systematic Review and Meta Analysis

Hu Yucai; Wang Yongxia; Li Bin; Du Tinghai; Zhu Mingjun

doi:10.3969/j.issn.16721349.2015.02.004

Abstract：Objective To systematical y review the clinical effects and safety of Shenxian Shengmai oral liquid (SSOL) for treatment of sinus bradycardia.Methods We searched in CNKI,VIP,CBM,Wan Fang DATA,PubMed,The Cochrane Library ,Embase,and other relevant databases,journals,Internet,proceeding and manufacturer data to identify randomized control ed trials (RCTs)on SSOL for treatment of sinus bradycardia from April 2000(clinical application)to November 2014.Two reviewers independently screened the liter-ature according to the inclusion and exclusion criteria,extracted the data,and assessed the methodological quality.Meta analyses were performed using RevMan 5. 3 software. The evaluation indexes included clinical therapeutic effects,mean heart rate,minimal heart rate,adverse events and safety indicators,etc. Results Five eligible studies included 453 patients. Compared with control groups,the results of descriptive analysis showed that SSOL group could precisely improve the clinical therapeutic effects in 3 RCTs. The results pointed out that SSOL could separately promote mean heart rate in 4 RCTs,total heart rate in 1 RCTs,minimal heart rate in 3 RCTs from Holter Monitor system.1 RCT revealed that SSOL group could obviously reduce SNRT,SACT in the bedside ECG.1 RCT showed that SSOL had rarely change than western medicine alone on the electrocardiogram PR interval and QRS duration.Ad-verse events and safety indicators were also not significantly different in RCTs above.Conclusion SSOL may be effective and safe for the patients of sinus bradycardia in improving the clinical symptoms and Increasing the heart rate.However,the methodological quality of study was low.The current evidence was insufficient to define the efficacy of the treatment,and further large scale,high quality randomized control ed trials were needed.